Kemia
Founded Year
2002Stage
Series C | AliveTotal Raised
$83.5MValuation
$0000Last Raised
$31M | 16 yrs agoAbout Kemia
Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.
Missing: Kemia's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Kemia's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Kemia
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Kemia is included in 3 Expert Collections, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Diabetes
1,903 items
Biopharma Tech
838 items
Kemia Patents
Kemia has filed 1 patent.
The 3 most popular patent topics include:
- Commerce websites
- Financial transaction tax
- International taxation
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/19/2019 | International taxation, Financial transaction tax, Payment systems, Commerce websites, Transfer tax | Application |
Application Date | 3/19/2019 |
|---|---|
Grant Date | |
Title | |
Related Topics | International taxation, Financial transaction tax, Payment systems, Commerce websites, Transfer tax |
Status | Application |
Latest Kemia News
Mar 26, 2020
Kemia Himon has been named director of financial aid at McDaniel College. Throughout her career, she has worked in higher education financial aid departments, previously serving as the financial aid director at Arkansas Baptist College, a private, historically black liberal arts college in Little Rock, Arkansas. At McDaniel, she oversees the college’s financial aid program of federal, state and institutional aid. More than 90 percent of students at McDaniel receive some type of financial assistance, and the college invests more than $40 million annually in need-based grants and merit scholarships to ensure that students from all kinds of financial backgrounds are able to experience a McDaniel education. Under Himon’s leadership, every McDaniel student is now assigned to a specific financial aid staff member who will assist them throughout their four years at McDaniel. Information in Movers and Shakers is provided by the submitter. To submit a Movers and Shakers item, visit https://thedailyrecord.com/movers/ .
Kemia Frequently Asked Questions (FAQ)
When was Kemia founded?
Kemia was founded in 2002.
Where is Kemia's headquarters?
Kemia's headquarters is located at 9393 Town Ctr. Drive #200, San Diego.
What is Kemia's latest funding round?
Kemia's latest funding round is Series C.
How much did Kemia raise?
Kemia raised a total of $83.5M.
Who are the investors of Kemia?
Investors of Kemia include Texas Pacific Group, Alta Partners, Forward Ventures, Novartis Venture Funds, J.P. Morgan & Co. and 8 more.
Who are Kemia's competitors?
Competitors of Kemia include Oligomerix, Elusys Therapeutics, Ocera Therapeutics, Threshold Pharmaceuticals, Probiodrug and 11 more.
Compare Kemia to Competitors
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.
SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.